| scholarly article | Q13442814 |
| P2093 | author name string | Angus J Clarke | |
| P2860 | cites work | A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes | Q36492194 |
| An informatics approach to analyzing the incidentalome | Q36514318 | ||
| Disclosure of incidental findings from next-generation sequencing in pediatric genomic research | Q36637088 | ||
| Incidental variants are critical for genomics | Q36817320 | ||
| Population screening for genetic susceptibility to disease | Q36904135 | ||
| Point-counterpoint. Patient autonomy and incidental findings in clinical genomics | Q37040336 | ||
| The legal risks of returning results of genomics research | Q37189098 | ||
| Disease-targeted sequencing: a cornerstone in the clinic | Q37205397 | ||
| Opportunities and challenges for the integration of massively parallel genomic sequencing into clinical practice: lessons from the ClinSeq project | Q37216033 | ||
| Managing incidental genomic findings: legal obligations of clinicians | Q37248265 | ||
| Description and pilot results from a novel method for evaluating return of incidental findings from next-generation sequencing technologies | Q37590819 | ||
| Improving the efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: an EGAPP methods update | Q37598607 | ||
| Incorporating genomics into breast and prostate cancer screening: assessing the implications | Q37614763 | ||
| Patients-in-waiting: Living between sickness and health in the genomics era. | Q37816055 | ||
| Neurodevelopmental hypothesis of schizophrenia | Q39777874 | ||
| With new prenatal testing, will babies with Down syndrome slowly disappear? | Q39970536 | ||
| Incidental swimming with millstones | Q41844734 | ||
| GWAS: heritability missing in action? | Q42352511 | ||
| Commentary on predictive genetic testing of minors: by Mand et al. | Q42647198 | ||
| Interpreting the role of de novo protein-coding mutations in neuropsychiatric disease | Q44731605 | ||
| Categorizing genetic tests to identify their ethical, legal, and social implications | Q45305010 | ||
| Evidence-based classification of recommendations on use of genomic tests in clinical practice: dealing with insufficient evidence | Q46258310 | ||
| Follow-up of carriers of BRCA1 and BRCA2 variants of unknown significance: variant reclassification and surgical decisions. | Q51017508 | ||
| A linguistic model of informed consent. | Q53628193 | ||
| Critical social theory approach to disclosure of genomic incidental findings | Q56773739 | ||
| Downsizing genomic medicine: approaching the ethical complexity of whole-genome sequencing by starting small | Q56777705 | ||
| A counselee-oriented perspective on risk communication in genetic counseling: Explaining the inaccuracy of the counseleesʼ risk perception shortly after BRCA1/2 test result disclosure | Q57947405 | ||
| Cancer genome landscapes | Q22242276 | ||
| Truncating mutations in NRXN2 and NRXN1 in autism spectrum disorders and schizophrenia | Q24297920 | ||
| Genetic testing in asymptomatic minors: background considerations towards ESHG Recommendations | Q24599256 | ||
| Clinical assessment incorporating a personal genome | Q24612653 | ||
| Genomics really gets personal: how exome and whole genome sequencing challenge the ethical framework of human genetics research | Q28601377 | ||
| Reflections on the cost of "low-cost" whole genome sequencing: framing the health policy debate | Q28661760 | ||
| Evolution and functional impact of rare coding variation from deep sequencing of human exomes | Q29617587 | ||
| Exome sequencing supports a de novo mutational paradigm for schizophrenia. | Q30405748 | ||
| Genetic evidence and integration of various data sources for classifying uncertain variants into a single model | Q33379396 | ||
| Self-guided management of exome and whole-genome sequencing results: changing the results return model | Q33566296 | ||
| A recurrent 16p12.1 microdeletion supports a two-hit model for severe developmental delay | Q33763087 | ||
| Behavioral and psychosocial effects of rapid genetic counseling and testing in newly diagnosed breast cancer patients: design of a multicenter randomized clinical trial | Q33789533 | ||
| Genetic testing in asymptomatic minors: Recommendations of the European Society of Human Genetics | Q34161654 | ||
| The psychosocial impact of Klinefelter syndrome and factors influencing quality of life | Q34183078 | ||
| Managing incidental findings and research results in genomic research involving biobanks and archived data sets | Q34205284 | ||
| Ethical and policy issues in genetic testing and screening of children | Q34328948 | ||
| Technical report: Ethical and policy issues in genetic testing and screening of children | Q34328987 | ||
| Mandatory extended searches in all genome sequencing: "incidental findings," patient autonomy, and shared decision making | Q34361977 | ||
| Assessing the risks and benefits of diagnosing genetic conditions with variable phenotypes through population screening: Klinefelter syndrome as an example. | Q35263417 | ||
| Newborn screening for Duchenne muscular dystrophy: a psychosocial study | Q35291626 | ||
| Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes | Q36096070 | ||
| Phenotypic heterogeneity of genomic disorders and rare copy-number variants | Q36387744 | ||
| P433 | issue | 1 | |
| P921 | main subject | medical ethics | Q237151 |
| research ethics | Q1132684 | ||
| sensitive information | Q2587068 | ||
| P304 | page(s) | 17-30 | |
| P577 | publication date | 2014-08-13 | |
| P1433 | published in | British Medical Bulletin | Q15750363 |
| P1476 | title | Managing the ethical challenges of next-generation sequencing in genomic medicine | |
| P478 | volume | 111 |
| Q55089341 | "Possibly positive or certainly uncertain?": participants' responses to uncertain diagnostic results from exome sequencing. |
| Q55074639 | Clinical providers' experiences with returning results from genomic sequencing: an interview study. |
| Q49918167 | Common Elements in Rare Kidney Diseases: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. |
| Q57386634 | Current controversies in prenatal diagnosis 2: should a fetal exome be used in the assessment of a dysmorphic or malformed fetus? |
| Q34774744 | Delivery of a clinical genomics service |
| Q92539562 | Diagnostic Yield of Next-Generation Sequencing in Patients With Chronic Kidney Disease of Unknown Etiology |
| Q38763892 | Discussing molecular testing in oncology care: Comparing patient and physician information preferences |
| Q57640341 | Ethics in genetic counselling |
| Q35916109 | Genomic analysis in the clinic: benefits and challenges for health care professionals and patients in Brazil |
| Q28602735 | Genomic intensive care: should we perform genome testing in critically ill newborns? |
| Q36286855 | Genomic newborn screening: public health policy considerations and recommendations |
| Q57643473 | Health professionals' and researchers' perspectives on prenatal whole genome and exome sequencing: 'We can't shut the door now, the genie's out, we need to refine it' |
| Q38874111 | Human Induced Pluripotent Stem Cells as a Platform for Personalized and Precision Cardiovascular Medicine. |
| Q47601953 | Impact of Receiving Secondary Results from Genomic Research: A 12-Month Longitudinal Study |
| Q87996412 | Implementation of personalized medicine in Central-Eastern Europe: pitfalls and potentials based on citizen's attitude |
| Q26750717 | Molecular genetics of early-onset Alzheimer's disease revisited |
| Q38659564 | Opening Pandora's box?: ethical issues in prenatal whole genome and exome sequencing |
| Q49339134 | Paediatric genomics: diagnosing rare disease in children |
| Q90712148 | Patient re-contact after revision of genomic test results: points to consider-a statement of the American College of Medical Genetics and Genomics (ACMG) |
| Q36556501 | Patients' views on incidental findings from clinical exome sequencing |
| Q92503675 | Pharmacogenomic Testing: Clinical Evidence and Implementation Challenges |
| Q37313653 | Postmortem genetic screening for the identification, verification, and reporting of genetic variants contributing to the sudden death of the young |
| Q40451424 | The Rise and Rise of Exome Sequencing. |
| Q38723850 | The genetic assessment of looked after children: common reasons for referral and recent advances |
| Q40784008 | The next generation of cancer management |
| Q42727399 | The nuanced negative: Meanings of a negative diagnostic result in clinical exome sequencing |
| Q92480890 | The use of fetal exome sequencing in prenatal diagnosis: a points to consider document of the American College of Medical Genetics and Genomics (ACMG) |
| Q40073039 | Towards a universal molecular microbiological test |
Search more.